Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03660748

Safety and Efficacy of MET-3 in Obese Human Subjects

A Phase I, Open-Label, Single-Centre Study of the Safety and Efficacy of Microbial Ecosystem Therapeutics (MET)-3 in Obese Human Subjects

Sponsor: Glycemic Index Laboratories, Inc

Conditions Obesity

Interventions MET-2

Updated 6 times since 2018 Last updated: Aug 10, 2020 Started: Oct 1, 2018 Primary completion: Jan 22, 2020 Completion: Jan 22, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Obesity, this trial is completed. The trial is conducted by Glycemic Index Laboratories, Inc and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Nov 2018 — Sep 2020 [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Oct 2018 — Nov 2018 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glycemic Index Laboratories, Inc
NuBiyota

Data source: NuBiyota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada